Table 2.
Clinical and virological relapses after cessation of nucleos(t)ide analogues in patients with negative HBeAg and undetectable viral DNA at the end of treatment
| All (N = 140) | ||
|---|---|---|
| First year | Second year | |
| Virological relapse | 62.0% (95% CI, 53.5–70.6%) | 79.2% (95% CI, 70.9–86.4%) |
| Clinical relapse | 28.4% (95% CI, 21.2–37.5%) | 42.9% (95% CI, 34.1–52.8%) |